Ensign Peak Advisors Inc Sells 945,041 Shares of Pfizer Inc. (NYSE:PFE)

Ensign Peak Advisors Inc lessened its position in shares of Pfizer Inc. (NYSE:PFEGet Rating) by 14.1% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 5,754,864 shares of the biopharmaceutical company’s stock after selling 945,041 shares during the period. Ensign Peak Advisors Inc owned approximately 0.10% of Pfizer worth $297,928,000 at the end of the most recent quarter.

Other institutional investors also recently made changes to their positions in the company. Ullmann Wealth Partners Group LLC boosted its holdings in shares of Pfizer by 6.2% during the first quarter. Ullmann Wealth Partners Group LLC now owns 5,759 shares of the biopharmaceutical company’s stock worth $298,000 after acquiring an additional 335 shares during the period. Red Door Wealth Management LLC boosted its holdings in shares of Pfizer by 8.6% during the first quarter. Red Door Wealth Management LLC now owns 109,620 shares of the biopharmaceutical company’s stock worth $5,675,000 after acquiring an additional 8,694 shares during the period. Capital City Trust Co. FL boosted its holdings in shares of Pfizer by 49.9% during the first quarter. Capital City Trust Co. FL now owns 8,464 shares of the biopharmaceutical company’s stock worth $438,000 after acquiring an additional 2,816 shares during the period. Colonial River Wealth Management LLC boosted its holdings in shares of Pfizer by 52.3% during the first quarter. Colonial River Wealth Management LLC now owns 20,988 shares of the biopharmaceutical company’s stock worth $1,087,000 after acquiring an additional 7,206 shares during the period. Finally, Annex Advisory Services LLC boosted its holdings in shares of Pfizer by 23.6% during the first quarter. Annex Advisory Services LLC now owns 10,279 shares of the biopharmaceutical company’s stock worth $532,000 after acquiring an additional 1,966 shares during the period. Institutional investors own 67.90% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on PFE shares. SVB Leerink reduced their price objective on Pfizer from $55.00 to $53.00 and set a “market perform” rating for the company in a report on Friday, July 29th. JPMorgan Chase & Co. set a $57.00 price target on shares of Pfizer in a research report on Tuesday, June 28th. Morgan Stanley dropped their price target on shares of Pfizer from $52.00 to $49.00 and set an “equal weight” rating for the company in a research report on Friday, July 8th. Berenberg Bank set a $50.00 price target on shares of Pfizer in a research report on Friday, May 27th. Finally, Barclays set a $50.00 price target on shares of Pfizer in a research report on Thursday, September 1st. Nine investment analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $57.33.

Pfizer Stock Down 0.2 %

Shares of PFE opened at $47.76 on Tuesday. Pfizer Inc. has a one year low of $40.94 and a one year high of $61.71. The company has a market cap of $268.05 billion, a P/E ratio of 9.35, a P/E/G ratio of 0.59 and a beta of 0.70. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.42 and a quick ratio of 1.20. The firm has a 50 day simple moving average of $49.61 and a two-hundred day simple moving average of $50.49.

Pfizer (NYSE:PFEGet Rating) last announced its quarterly earnings results on Thursday, July 28th. The biopharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.95 by $0.09. The company had revenue of $27.74 billion during the quarter, compared to the consensus estimate of $26.20 billion. Pfizer had a net margin of 28.92% and a return on equity of 43.18%. The company’s revenue for the quarter was up 46.8% compared to the same quarter last year. During the same period in the prior year, the business earned $1.07 earnings per share. Research analysts forecast that Pfizer Inc. will post 6.54 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 6th. Stockholders of record on Wednesday, June 29th were issued a dividend of $0.40 per share. The ex-dividend date of this dividend was Thursday, July 28th. This represents a $1.60 annualized dividend and a dividend yield of 3.35%. Pfizer’s dividend payout ratio (DPR) is presently 31.31%.

Pfizer Company Profile

(Get Rating)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.

Featured Articles

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFEGet Rating).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.